Concept Life Sciences has entered a strategic partnership with OpenBench to accelerate early-stage drug discovery for biotechnology companies through a success-based artificial intelligence model aimed at reducing cost, scientific uncertainty and development timelines.
The collaboration combines OpenBench’s structure-based AI hit discovery platform with Concept Life Sciences’ medicinal chemistry, in vitro screening and validation expertise. The companies said the partnership is designed to help biotech firms move from biological target identification to validated hit series in as little as six months while minimizing financial risk during the early stages of research.
The partnership comes at a time when biotech companies continue to face funding pressures and rising development costs, increasing demand for more capital-efficient approaches to research and development.
Under the model, OpenBench will perform large-scale virtual screening of trillions of compounds using its AI-driven platform to identify potential chemical candidates against selected biological targets. The most promising compounds will then be synthesized and advanced to Concept Life Sciences for laboratory testing, screening and biological validation.
Unlike traditional discovery agreements that typically require substantial upfront investment, OpenBench said it will fund all early discovery activities and charge biotech clients only after validated hits are delivered. The fee-for-success structure shifts much of the early-stage financial and scientific risk away from clients, allowing smaller biotechnology companies to pursue programs without significant initial spending.
Once validated hit compounds are identified, Concept Life Sciences will extend development through its integrated “design-make-test” platform, which combines medicinal chemistry, screening and optimization capabilities intended to move promising candidates toward clinical development more efficiently.
The companies said the integrated approach could help accelerate the generation of high-quality chemical starting points for drug programs spanning multiple therapeutic areas and disease indications.
Steven L. Holshouser, head of business development for North America at Concept Life Sciences, said biotechnology companies are increasingly seeking faster and lower-risk routes to promising chemical leads, particularly amid constrained financing conditions.
Holshouser said combining OpenBench’s success-based model with Concept Life Sciences’ development capabilities provides clients with a more efficient route from target selection to validated and potentially developable compounds.
Meanwhile, Lewis Martin, chief scientific officer at OpenBench, said the partnership is intended to remove one of the biggest barriers in early drug discovery: upfront cost and uncertainty. He said OpenBench’s model enables companies to receive validated chemical leads before committing financial resources, allowing biotech firms to focus spending on programs with stronger development potential.
Industry observers have increasingly highlighted the use of AI-driven drug discovery technologies as a means to shorten research timelines and improve efficiency, particularly as smaller biotechnology firms navigate tighter investment conditions.
By pairing AI-enabled virtual screening with laboratory validation and chemistry capabilities, Concept Life Sciences and OpenBench aim to offer biotech clients an alternative to traditional discovery models, enabling faster pipeline development while reducing the financial and operational burden often associated with early-stage pharmaceutical research.